Description
VERSAVO 400 MG is a specialized anticancer monoclonal antibody containing Bevacizumab. Manufactured by Dr. Reddy’s Laboratories, it is a targeted therapy designed to treat various advanced malignancies by inhibiting angiogenesis—the process by which tumors grow their own blood supply. By blocking the Vascular Endothelial Growth Factor (VEGF) protein, Versavo starves the tumor of oxygen and nutrients, effectively slowing or stopping cancer progression. It is a vital component in the treatment of metastatic colorectal cancer, non-small cell lung cancer, kidney cancer, glioblastoma (brain cancer), and ovarian cancer.
